The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies
Open accessAbstract
Purpose: GSK461364 is an ATP-competitive inhibitor of polo-like kinase 1 (Plk1). A phase I study of two schedules of intravenous GSK461364 was conducted. Experimental Design: GSK461364 was administered in escalating doses to patients with solid malignancies by two schedules, either on days 1, 8, and 15 of 28-day cycles (schedule A) or on days 1, 2, 8, 9, 15, and 16 of 28-day cycles (schedule B). Assessments included pharmacokinetic and pharmacodynamic profiles, as well as marker expression studies in pretreatment tumor biopsies. Results: Forty patients received GSK461364: 23 patients in schedule A and 17 in schedule B. Dose-limiting toxicities (DLT) in schedule A at 300 mg (2 of 7 patients) and 225 mg (1 of 8 patients) cohorts included grade 4 neutropenia and/or grade 3–4 thrombocytopenia. In schedule B, DLTs of grade 4 pulmonary emboli and grade 4 neutropenia occurred at 7 or more days at 100 mg dose level. Venous thrombotic emboli (VTE) and myelosuppression were the most common grade 3–4, drug-related events. Pharmacokinetic data indicated that AUC (area under the curve) and Cmax (maximum concentration) were proportional across doses, with a half-life of 9 to 13 hours. Pharmacodynamic studies in circulating tumor cells revealed an increase in phosphorylated histone H3 (pHH3) following drug administration. A best response of prolonged stable disease of more than 16 weeks occurred in 6 (15%) patients, including 4 esophageal cancer patients. Those with prolonged stable disease had greater expression of Ki-67, pHH3, and Plk1 in archived tumor biopsies. Conclusions: The final recommended phase II dose for GSK461364 was 225 mg administered intravenously in schedule A. Because of the high incidence (20%) of VTE, for further clinical evaluation, GSK461364 should involve coadministration of prophylactic anticoagulation. Clin Cancer Res; 17(10); 3420–30. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542
Cited by
Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics
Gutteridge, R. E. A., Ndiaye, M. A., Liu, X., & Ahmad, N. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0897 · Cited by 406
Smart Nanomaterials in Cancer Theranostics: Challenges and Opportunities
Kashyap, B. K., Singh, V. V., Solanki, M. K., Kumar, A., Ruokolainen, J., & Kesari, K. K. (2023) · ACS Omega · doi:10.1021/acsomega.2c07840 · Cited by 348
Present and Future Perspective on PLK1 Inhibition in Cancer Treatment
Chiappa, M., Petrella, S., Damia, G., Broggini, M., Guffanti, F., & Ricci, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.903016 · Cited by 120
ScFv‐Decorated PEG‐PLA‐Based Nanoparticles for Enhanced siRNA Delivery to Her2+ Breast Cancer
Dou, S., Yang, X., Xiong, M., Sun, C., Yao, Y., Zhu, Y., & Wang, J. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201400037 · Cited by 39
Banerjee, S., Zagórska, A., Deak, M., Campbell, D. G., Prescott, A. R., & Alessi, D. R. (2014) · Biochemical Journal · doi:10.1042/bj20140408 · Cited by 32
Metadata
- Authors
- Olmos, D., Barker, D., Sharma, R., Brunetto, A. T., Yap, T. A., Taegtmeyer, A. B., Barriuso, J., Medani, H., Degenhardt, Y. Y., Allred, A. J., Smith, D. A., Murray, S. C., Lampkin, T. A., Dar, M. M., Wilson, R., de Bono, J. S., & Blagden, S. P.
- Venue
- Clinical Cancer Research
- Published
- 2011-05-15
- Volume
- 17
- Issue
- 10
- Pages
- 3420-3430
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2102126248
- Cited by
- 169
- References
- 1
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-2946
- The paper
- Olmos, D., Barker, D., Sharma, R., Brunetto, A. T., Yap, T. A., Taegtmeyer, A. B., Barriuso, J., Medani, H., Degenhardt, Y. Y., Allred, A. J., Smith, D. A., Murray, S. C., Lampkin, T. A., Dar, M. M., Wilson, R., de Bono, J. S., & Blagden, S. P. (2011). Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-2946
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.